Hasan T Kirat1, Ersin Ozturk, Ian C Lavery, Ravi P Kiran. 1. Cleveland Clinic Foundation, Department of Colorectal Surgery, Digestive Disease Institute-A30, 9500 Euclid Ave., Cleveland, OH 44195, USA.
Abstract
BACKGROUND: We evaluated factors associated with an increased preoperative carcinoembryonic antigen (CEA) level for colon cancer patients undergoing elective curative surgery and assessed whether this was associated with prognosis when accounting for other potential confounders. METHODS: Prospectively accrued data of patients with stage I, II, and III colon cancer undergoing surgery (1980-2008) were retrieved retrospectively. Patients with a preoperative CEA level greater than 5 ng/mL (group B) were compared with those with a CEA level of 5 ng/mL or less (group A). RESULTS: There were 651 patients (379 men) with a median age of 67 years (range, 21-94 y) and a median follow-up period of 5.9 years. Groups A (n = 451) and B (n = 200) had similar ages and tumor locations. Group B had larger tumors; more patients with T3 and N1/N2; and more patients with stage II/III tumors, and hence greater use of chemotherapy (P = .04). On multivariate analysis, patient age, tumor stage, and differentiation were associated with oncologic outcomes. A CEA level greater than 5 ng/mL was not associated independently with recurrence, recurrence-free survival (P = .47), or overall survival (P = .3). CONCLUSIONS: An increased preoperative CEA level is a marker for a more advanced tumor stage. For adequately staged patients, a high preoperative CEA level is not associated independently with oncologic outcomes.
BACKGROUND: We evaluated factors associated with an increased preoperative carcinoembryonic antigen (CEA) level for colon cancerpatients undergoing elective curative surgery and assessed whether this was associated with prognosis when accounting for other potential confounders. METHODS: Prospectively accrued data of patients with stage I, II, and III colon cancer undergoing surgery (1980-2008) were retrieved retrospectively. Patients with a preoperative CEA level greater than 5 ng/mL (group B) were compared with those with a CEA level of 5 ng/mL or less (group A). RESULTS: There were 651 patients (379 men) with a median age of 67 years (range, 21-94 y) and a median follow-up period of 5.9 years. Groups A (n = 451) and B (n = 200) had similar ages and tumor locations. Group B had larger tumors; more patients with T3 and N1/N2; and more patients with stage II/III tumors, and hence greater use of chemotherapy (P = .04). On multivariate analysis, patient age, tumor stage, and differentiation were associated with oncologic outcomes. A CEA level greater than 5 ng/mL was not associated independently with recurrence, recurrence-free survival (P = .47), or overall survival (P = .3). CONCLUSIONS: An increased preoperative CEA level is a marker for a more advanced tumor stage. For adequately staged patients, a high preoperative CEA level is not associated independently with oncologic outcomes.
Authors: Mikaela L Garland; Ryash Vather; Noah Bunkley; Maria Pearse; Ian P Bissett Journal: Int J Colorectal Dis Date: 2014-01-14 Impact factor: 2.571
Authors: L Chen; B Jiang; Z Wang; M Liu; H Yang; J Xing; C Zhang; Z Yao; N Zhang; M Cui; X Su Journal: Clin Transl Oncol Date: 2013-07-17 Impact factor: 3.405
Authors: Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele Journal: J Cancer Date: 2014-01-01 Impact factor: 4.207